PRESS RELEASES
02/2021

Sagimet Biosciences Raises $80 Million in Crossover Financing

Altium Capital, HM Capital, Invus, and PFM Health Sciences join previous investors Ascletis, Kleiner Perkins, New Enterprise Associates, Rock Springs Capital, and two undisclosed leading public equity healthcare investors in…
Read More
PRESS RELEASES
11/2020

ASC40 (TVB-2640) Phase 2 NASH Trial Completed Patient Enrollment in China

Shanghai, China and San Francisco, California, United States, November 19,2020 – Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX:1672) and Sagimet Biosciences Inc. jointly announced…
Read More
NASH
11/2020

Novel, first-in-class, fatty acid synthase inhibitor, TVB-2640 versus placebo demonstrates clinically significant reduction in liver fat by MRI-PDFF in NASH

AASLD
Read More
PRESS RELEASES
10/2020

Sagimet to Present Data from Phase 2 FASCINATE-1 Trial of TVB-2640 in NASH at AASLD’s The Liver Meeting Digital Experience™ 2020

San Mateo, California, October 6, 2020 – Sagimet Biosciences, a clinical-stage biotechnology company, announced today that new results from its Phase 2 FASCINATE-1 trial of TVB-2640 in nonalcoholic steatohepatitis (NASH)…
Read More
Oncology
09/2020

TVB-2640 with Bevacizumab in Relapsed High-grade Astrocytoma

European Society for Medical Oncology (ESMO) Congress
Read More
brain_imagination-2560x1440
NASH
08/2020

Novel, first-in-class, fatty acid synthase inhibitor, TVB-2640 versus placebo demonstrates clinically significant reduction in liver fat by MRI-PDFF in NASH

EASL International Liver Congress
Read More
NASH
08/2020

The FASN inhibitor TVB-2640 is efficacious in a new 3D human liver microtissue model of NASH

EASL International Liver Congress
Read More
NASH
07/2020

Fatty Acid Synthase Inhibitor TVB-2640 Reduces Hepatic de Novo Lipogenesis in Males With Metabolic Abnormalities

Hepatology 2020
Read More
PRESS RELEASES
06/2020

Sagimet Announces Positive Topline Results in 12-week NASH Phase 2 Clinical Trial of FASN Inhibitor TVB-2640

Oral FASN inhibitor TVB-2640 significantly reduces liver fat with a 61% responder rate Demonstrates improvement in markers of liver function and fibrosis Results to be presented on August 28 at…
Read More
PRESS RELEASES
03/2020

Data on Sagimet’s Lead Candidate TVB-2640 to be Presented at EASL ILC 2020

Phase 2 (FASCINATE-1) clinical data in NASH accepted for late-breaker oral presentation; preclinical data accepted for poster presentation San Mateo, California, March 31, 2020 – Sagimet Biosciences, a clinical-stage biotechnology…
Read More